Skip to main content

Advertisement

Log in

The individual Pityriasis Rubra Pilaris area and severity index (iPRPASI): validity, reliability, and responsiveness of a novel patient-reported severity tool

  • Short Report
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Data availability

The data in this study are available on reasonable request from the corresponding author [TMG] upon approval of the Institutional Review Board.

References

  1. Boudreaux BW, Pincelli TP, Bhullar PK, Patel MH, Brumfiel CM, Li X, Heckman MG, Pittelkow MR, Mangold AR, Sluzevich JC (2022) Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis. Br J Dermatol 187(5):650–658. https://doi.org/10.1111/bjd.21708

    Article  CAS  PubMed  Google Scholar 

  2. Chularojanamontri L, Griffiths CE, Chalmers RJ (2013) The Simplified Psoriasis Index (SPI): a practical tool for assessing psoriasis. J Invest Dermatol 133(8):1956–62. https://doi.org/10.1038/jid.2013.138

    Article  CAS  PubMed  Google Scholar 

  3. Haynes D, Strunck JL, Topham CA, Ortega-Loayza AG, Kent G, Cassidy PB, Hu R, Choate K, Wang Z, Liu Y, Greiling TM (2020) Evaluation of Ixekizumab treatment for patients with pityriasis rubra pilaris: a single-arm trial. JAMA Dermatol 156(6):668–675. https://doi.org/10.1001/jamadermatol.2020.0932

    Article  PubMed  Google Scholar 

  4. Ji-Xu A, Lei DK, Worswick S, Maloney NJ, Kim MM, Cutler L (2022) Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris. Br J Dermatol 187(6):1024–1026. https://doi.org/10.1111/bjd.21792. (Epub 2022 Aug 18 PMID: 35895853)

    Article  PubMed  Google Scholar 

  5. Velasco RC, Cutler B, McCue W, Greiling TM (2023) The comprehensive impact of pityriasis rubra pilaris on physical symptoms, mental health, and activities of daily living: a mixed methods study. JEADV Clin Pract. https://doi.org/10.1002/jvc2.107

    Article  Google Scholar 

Download references

Funding

Clinical data was collected while subjects were enrolled in investigator-initiated clinical trials funded by Eli Lilly and Co. and Janssen Scientific Affairs. The funders had no role in the collection or analysis of data, nor the decision to publish.

Author information

Authors and Affiliations

Authors

Contributions

Conceptualization: TG; Methodology: TG, CS; Formal analysis and investigation: all authors; Writing–original draft preparation: CS; Writing–reviewing and editing: all authors; Funding acquisition: TG.

Corresponding author

Correspondence to Teri M. Greiling.

Ethics declarations

Conflict of interest

Teri Greiling has received research grants to study PRP from Eli Lilly and Co, Janssen Scientific Affairs, and Janssen Biotech Inc; consulted with AbbVie; and is an author on PRP for UpToDate and VisualDx. Connie Shao and Rose Velasco declare no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shao, C., Velasco, R. & Greiling, T.M. The individual Pityriasis Rubra Pilaris area and severity index (iPRPASI): validity, reliability, and responsiveness of a novel patient-reported severity tool. Arch Dermatol Res 315, 2933–2935 (2023). https://doi.org/10.1007/s00403-023-02682-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-023-02682-7

Navigation